Stockreport

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas [Yahoo...

Lantheus Holdings, Inc.  (LNTH) 
Last lantheus holdings, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.lantheus.com/investor-relations
PDF best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase 1/ [Read more]